Enterprise Value
-26.36M
Cash
141.6M
Avg Qtr Burn
-26.38M
Short % of Float
11.49%
Insider Ownership
1.85%
Institutional Own.
92.89%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Zelnecirnon / RPT193 (CCR4 antagonist) Details Atopic dermatitis | Phase 2b Update | |
Tivumecirnon / FLX475 (CCR4 antagonist) Details Cancer, Solid tumor/s, Non-small cell lung carcinoma | Phase 2 Data readout | |
Zelnecirnon/ RPT193 (CCR4 antagonist) Details Asthma, Lung disease | Phase 2a Update |